Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Governance of Diabetes Management in Non-specialistic Hospital Settings

22 dicembre 2015 aggiornato da: Ivana Zavaroni, Azienda Ospedaliero-Universitaria di Parma
The prevalence of diabetes among inpatients in medical wards, surgery and intensive care units in Italy is approximatively 12-25%. The management of in hospital diabetes and hyperglycemia is complex and requires a specific training for physicians and nurses in non-specialist settings. The overall project aims at the implementation of a "best practice" model of care for hospitalized diabetic patients in non-specialist settings.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The project aims at defining a model of care for hospitalized diabetic patients in non-specialist settings based on the national and international recommendations. This is a cluster randomized study to evaluate the efficacy of a structured education training program for physicians and nurses in improving an ad hoc composite performance score of diabetes management and some clinical outcomes. The study will be carried out in 6 hospitals of the Emilia-Romagna region in Italy and it will involve 3 different wards (internal medicine, intensive care unit, surgery). For each hospital one intervention and two controls wards will be randomly identified.

At baseline the clinical management of patients with stress hyperglycemia/diabetes will be assessed in all participating wards over a 3-month period. Then, a structured educational program regarding the management of stress hyperglycemia/diabetes in the inpatient setting will be carried out only in the intervention wards. This program will last 2 months. Health care professionals also will be trained in the regular use of appropriate management tools (hyperglycemia dedicated standard operation procedures, audits, etc.).

Three months after the end of the educational program, the 3-month assessment of clinical management of patients with stress hyperglycemia/diabetes will be repeated in all participating wards.

The assessment of clinical management of stress hyperglycemia/diabetes will be based on a set of clinical performance indicators concerning 5 major domains (admission assessment, glucose monitoring, medical therapy, management of consults, management of discharge). These indicators will be used to define a composite performance score of appropriateness and efficacy. The highest score (1) will be assigned when the indicator is monitored, the lowest (0) when the indicator will be not detected, according to the scoring method previously reported by Rossi et al. Therefore, the score of each domain will range between 0 and the number of indicators used to assess appropriateness and efficacy of that domain.

Domain 1 - Initial assessment: score 0-5

  • records of admission glycemia
  • records of fasting plasma glucose
  • records of HbA1c
  • appropriate diagnosis of stress hyperglycemia/diabetes mellitus according to ADA
  • records of history of presence/absence of pharmacological diabetes therapy

Domain 2 - Glucose monitoring: score 0-4

  • appropriate glucose monitoring: at least 80% of three daily preprandial glycemia or, in critically ill patients, monitoring according to the specific algorithm used in the ward
  • presence and use of specific forms for glucose records
  • presence of ward standing orders to recognize and correct hypoglycemia
  • presence of ward standing orders to monitor and manage glucose in critically ill patients (Critically ill patients are defined as patients who require intensive care for acute critical illnesses, such as myocardial infarction, stroke, septic shock or severe respiratory failure, requiring intensive or semi-intensive therapy and, as a rule, not taking food orally during the first 24-72 hours)

Domain 3 - Medical therapy: score 0-2

  • records of time and dose of insulin therapy
  • interruption of Metformin therapy when indicated (correct indications to discontinuation of Metformin therapy were: any critical illness, acute renal, cardiac and/or respiratory failure, surgery or iodinated contrast agents administration.)

Domain 4 - Consults: score 0-2

  • request and records of diabetes specialist consult
  • request and records of nursing consult

Domain 5 - Management of discharge: score 0-3

  • planning of diabetes follow-up visit after hospitalization
  • patient education for home blood glucose self-monitoring
  • patient education for all other aspects of diabetes management

The sum of the scores of each domain from 1 to 5 is the composite performance score.

The following clinical outcomes will be recorded both at baseline and 3 months after the end of the educational program in all participating wards.:

  • all hypoglycemic events (blood glucose ≤ 70 mg/dl)
  • severe hypoglycemic events (blood glucose ≤ 40 mg/dl with or without clouding of consciousness)
  • difference between plasma glycemia at admission and mean plasma glucose during the last-48-hours before discharge
  • achievement of glycemic goals: 4 consecutive blood glucose levels ≤ 130 mg/dl (preprandial) or ≤ 180 mg/dl (postprandial), or 4 consecutive blood glucose levels between 140 and 180 mg/dl in critically ill patients
  • survival
  • discharge condition: a score of 0 will be assigned in case of death or transfer to a higher intensity ward and score 1 in all other cases, i.e. home discharge or transferral to a lower intensity ward.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

1449

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Bologna, Italia
        • AUSL Ospedale Maggiore
      • Ferrara, Italia, 44121
        • Azienda Ospedaliero-Universitaria
      • Modena, Italia
        • AUSL Carpi
      • Parma, Italia, 43126
        • Azienda Ospedaliero-Universitaria Parma
      • Piacenza, Italia, 29121
        • AUSL Piacenza
      • Reggio Emilia, Italia, 42027
        • AUSL Montecchio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • patients with type 2 or type 1 diabetes or stress hyperglycemia

Exclusion Criteria:

  • age <18,
  • patients hospitalized for diabetic complications: ketoacidosis, hyperosmolar syndrome, hypoglycemic coma, pregnant diabetics or gestational diabetes

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: educational training
implementation of a structured educational program for physicians and nurses
Nessun intervento: no educational training
no educational training wards

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Composite performance score computed as the sum of the performance scores of all 5 domains of appropriateness and efficacy in both the intervention and the control wards
Lasso di tempo: 11 months
Efficacy of educational training will be evaluated as absolute change of the performance scores after the intervention compared to baseline in the two groups
11 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
hypoglycemic events in the intervention and control wards
Lasso di tempo: 11 months
rate difference of hypoglycemia events (blood glucose ≤ 70 mg/dl) in the intervention and control wards
11 months
severe hypoglycemic events in the intervention and control wards
Lasso di tempo: 11 months
rate difference of severe hypoglycemia events (blood glucose ≤ 40 mg/dL with or without clouding of consciousness) in the intervention and control wards
11 months
difference between plasma glycemia at admission and mean plasma glucose during the last-48-hours before discharge
Lasso di tempo: 11 months
difference between plasma glycemia at admission and mean plasma glucose during the last-48-hours before discharge
11 months
achievement of glycemic goals in the intervention and control wards
Lasso di tempo: 11 months
number of patients that achieve glycemic goals: 4 consecutive blood glucose levels ≤ 130 mg/dl (preprandial) or ≤ 180 mg/dl (postprandial), or 4 consecutive blood glucose levels between 140 and 180 mg/dl in critically ill patients
11 months
survival rate during hospitalization in the intervention and control wards
Lasso di tempo: 11 months
survival rate during hospitalization (score 1 for survival, score 0 for death)
11 months
discharge condition in the intervention and control wards
Lasso di tempo: 11 months
a score of 0 will be assigned in case of death or transfer to a higher intensity ward and score 1 in all other cases, i.e. home discharge or transferral to a lower intensity ward.
11 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ivana Zavaroni, MD, Azienda Ospedaliero-Universitaria Parma

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 gennaio 2012

Completamento primario (Effettivo)

1 marzo 2015

Completamento dello studio (Effettivo)

1 marzo 2015

Date di iscrizione allo studio

Primo inviato

19 novembre 2015

Primo inviato che soddisfa i criteri di controllo qualità

22 dicembre 2015

Primo Inserito (Stima)

29 dicembre 2015

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

29 dicembre 2015

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 dicembre 2015

Ultimo verificato

1 dicembre 2015

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • AOParma

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su educational training

Sottoscrivi